Navigation Links
Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Date:3/7/2011

NEW YORK, March 7, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced that the final dataset from the Phase 3 short-term clinical trial of Zerenex™ (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis has been selected for oral presentation at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 26-30, 2011 in Las Vegas, Nevada.  

The Zerenex data will be presented by David S. Goldfarb, M.D., Chief of Nephrology, New York VA Medical Center, Professor of Medicine & Physiology, NYU School of Medicine, in a presentation entitled "Advantages and Disadvantages of Existing Phosphate Binders."  This presentation will be the first part in a session entitled "Future Directions and Challenges for Phosphate Binders."  The session will take place on Thursday, April 28, 2011, 8:00am – 8:30am PT.  

On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.  

In accordance with the Company's Special Protocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc.  Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways ass
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
4. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
6. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
7. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
10. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind Entwicklung ... Daten aus Plasmaproben zur Steuerung von Therapien mit ... kann  Neuer Bluttest basiert auf QIAGENs ... soll auf Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2011 Orexigen ® Therapeutics, Inc. (Nasdaq: OREX ... Securities Healthcare Conference in New York. The presentation is scheduled for ... listen to the live webcast or a replay of the presentation, ... at www.orexigen.com . A replay will be available for 14 ...
... MONMOUTH JUNCTION, N.J., Sept. 26, 2011 Insmed Incorporated (Nasdaq ... President and CEO of Insmed, will be presenting a corporate ... Wednesday, September 28, 2011, at 11:30 AM ET, in New ... available on Insmed,s website, http://www.insmed.com .  The webcast will ...
Cached Medicine Technology:Insmed to Present at Sixth Annual JMP Securities Healthcare Conference 2
(Date:7/28/2014)... H2T Elite Dryland Training will be opening up ... Street in Toronto, H2T is focused on capturing ... a state of the art facility that specializes in fitness, ... gyms out there for people 18 and older but nothing ... be home to many elite athletes that will train sport ...
(Date:7/28/2014)... access to a website containing information about the measles, ... way of increasing its uptake, new University of Leeds ... via a website containing information helping parents make a ... vaccination to the NHS than informing them solely via ... leaflet providing information about the vaccine. In each case, ...
(Date:7/28/2014)... study has found that following a healthy lifestyle may ... syndrome. Published early online in CANCER , a ... indicate that children with cancer and adults who had ... how their lifestyle may influence their long-term health. ... to be at increased risk for the metabolic syndrome, ...
(Date:7/28/2014)... 28, 2014 According to the Greek God ... a comprehensive fitness guide that teaches men how to completely ... , Vkool reveals in its review that inside the Greek ... Ways to gain the maximum muscle fiber recovery ... muscle and avoid fat gain , Ways to ...
(Date:7/28/2014)... 2014 TherapySites, the leading ... announced today its affiliation with the Illinois Association ... relationship allows TherapySites to continue to extend their online ... promotional offers. , “There has been a fundamental shift ... With nearly 3 billion Internet users, it is so ...
Breaking Medicine News(10 mins):Health News:FS Local Community Member H2T Elite Dryland Training Is Set to Open Its Doors 2Health News:Online information most cost-effective means of increasing MMR uptake, research finds 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2
... CardioCareLive, the world,s largest live online cardiology congress ... Medicine, today announced three new complimentary Continuing Medical ... days on Tuesday June 28th and Wednesday June ... and internal medicine and family care physicians in ...
... latest episode in the American Chemical Society,s (ACS) ... focuses on new blood test that can quickly ... bacterium that,s become a global threat, significantly improving ... Staphylococcus aureus, or simply MRSA. The podcast explains ...
... 24 (HealthDay News) -- Rain-making bacteria may shed some ... the Earth,s precipitation cycle, new research shows. ... meeting of the American Society for Microbiology in New ... of hailstones, suggesting that airborne microorganisms may trigger precipitation, ...
... knowledge of tuberculosisas well as in the practices, programs ... with human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) ... community. Research in the June issue of The ... use of 18F-FDG positron emission tomography (PET) scans can ...
... MA Electronic medical records (EMRs) have been in use ... utilization in recent years, due in part to research supporting ... become a standard in medical care, there is a need ... be refined. A group of researchers from Brigham and Women,s ...
... you may want to think twice before shooting hundreds of ... study from MIT neuroscientists shows that the most memorable photos ... and human-scale objects. Landscapes? They may be beautiful, but they ... are not the same," says MIT graduate student Phillip Isola, ...
Cached Medicine News:Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 3Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Airborne Germs May Spur Rain, Snow, Hail 2Health News:PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients 2Health News:MIT research: What makes an image memorable? 2Health News:MIT research: What makes an image memorable? 3
... NPB-290 and NPB-295 Pulse Oximeters are ... accuracy, reliability and proven signal processing ... perfused patients. Equipped with Oxismart Advanced ... these pulse oximeters identify electronic and ...
... Oximeter with Oxismart XL Advanced Signal Processing ... nonspecific noise to find the pulse and ... rate values. , ,The N395 monitor ... a breakthrough in clinician-programmable alarm sensitivity for ...
The Model 5340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery....
Medicine Products: